Cardiovascular Drugs Market Size, Share, Trend, Outlook, Future Growth Analysis And Synthesis 2018 - 2026 Some of the common cardiovascular diseases include hypertensive heart disease, rheumatic heart disease, ischemic heart disease, inflammatory heart disease, and cerebrovascular heart disease. Major problems associated with hypertensive heart disease include angina, hypertrophy, and heart failure. These problems are caused due to high blood pressure in the heart’s arteries and muscles, which causes narrowing of arteries and thickening and enlargement of heart. The global cardiovascular drug market is primarily driven by increase in prevalence of heart diseases coupled with rising geriatric population and lifestyle related diseases. In order to cater to this increasing population suffering from cardiovascular diseases, drugs for treatment and prevention for these diseases is required. Rising number of diabetic patients is also expected to be another factor for growth of the global cardiovascular drugs market. According American Diabetes Association, in 2015, 30.3 Americans had diabetes, which is 9.4% of the total U.S population. Download PDF Brochure of This Business Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1167 Manufacturers in the market are focusing on mergers and acquisition and new product launches, which is positively affecting the market growth. However, stringent drug approval process and side effects of some cardiovascular drugs hamper growth of the global cardiovascular drugs market. Moreover, the patent expiry of various blockbuster drugs is also expected to adversely affect revenue growth of the global cardiovascular drugs market. According to American Heart Association (AHA), in 2013, cardiovascular diseases accounted for over 17.3 million deaths globally, representing 31% of all global deaths. The global number is expected to rise to 23.6 million by 2030. In 2010, the global burden of cardiovascular diseases was US$ 863 billion, and it is expected to rise to US$1044 billion by 2030. Around 2,200 U.S. citizens die due to cardiovascular diseases, everyday, which is one death in every 40 seconds. Moreover, coronary heart disease accounts for (45.1%) of the total cardiovascular disease, followed by stroke (16.5%), high blood pressure (9.1%), heart failure (8.5%), diseases related to arteries (3.2%), and other cardiovascular diseases in the U.S. Report includes chapters which deeply display the following deliverable about industry : • Cardiovascular Drugs Market Research Objective and Assumption • Cardiovascular Drugs Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Cardiovascular Drugs Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Cardiovascular Drugs Market, By Regions • Cardiovascular Drugs Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Cardiovascular Drugs Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Cardiovascular Drugs Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Cardiovascular Drugs Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Cardiovascular Drugs Market - Competitor Analysis Some of the major players operating in the global cardiovascular drugs market are Pfizer Inc., Bayer AG., Novartis AG., Merck and Co. Inc., AstraZeneca Plc, Bristol Myers Squibb Company, Abbott Laboratories, Sun Pharma Industries, Gilead Sciences Inc., Otsuka Holdings Co., Ltd. Takeda Pharmaceutical Company Ltd, Eli Lilly and Company, and Johnson & Johnson. Global Cardiovascular Drugs Market Taxonomy On the basis of drug class, the global cardiovascular drugs market is segmented into: • Anti-Hypertensive • Anti-Hyperlipidemics • Anti-Coagulants • Anti-Arrhythmic • Anti-Fibrinolytic • Others (antianginal drugs, cardiac glycosides, and anti-ischemic drugs) On the basis of distribution channels, the global cardiovascular drugs market is segmented into: • Retail Pharmacies • Hospital Pharmacies • Online Pharmacies To know the latest trends and insights prevalent in the cardiovascular drugs market, click the link below: https://www.coherentmarketinsights.com/ongoing-insight/cardiovascular-drugs-market1167 About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com
Some of the common cardiovascular diseases include hypertensive heart disease, rheumatic heart disease, ischemic heart disease, inflammatory heart disease, and cerebrovascular heart disease.
© Copyright 2024 Paperzz
